Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia

We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven pati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jabbour, Elias, Garcia-Manero, Guillermo, Cortes, Jorge, Ravandi, Farhad, Plunkett, William, Gandhi, Varsha, Faderl, Stefan, O’Brien, Susan, Borthakur, Gautam, Kadia, Tapan, Burger, Jan, Konopleva, Marina, Brandt, Mark, Huang, Xuelin, Kantarjian, Hagop
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3859239/
https://ncbi.nlm.nih.gov/pubmed/22534616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.03.003
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items